Orange Book product · Generic (ANDA)
PIPERACILLIN AND TAZOBACTAM
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM
At a glance
Oct 12, 2023
Approved
Generic (ANDA)
Application
Not listed
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Oct 12, 2023
2 yr 9 mo ago
Today
Pharmaceutical detail
Active ingredient
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM
Strength
EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL
Dosage form
INJECTABLE
Route
INJECTION
TE code
Not listed
Application
ANDA 217409
Product number
002
Marketing status
DISCN
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of PIPERACILLIN SODIUM; TAZOBACTAM SODIUM
- 2025PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINERBrand (NDA)
NDA 206056 · B BRAUN MEDICAL
- 1998ZOSYN IN PLASTIC CONTAINERBrand (NDA)
NDA 050750 · BAXTER HLTHCARE CORP
- 1993ZOSYNBrand (NDA)
NDA 050684 · WYETH PHARMS
- 2023PIPERACILLIN AND TAZOBACTAMGeneric (ANDA)
ANDA 217243 · SHANDONG
- 2021PIPERACILLIN AND TAZOBACTAMGeneric (ANDA)
ANDA 208674 · SAGENT PHARMS INC
- 2021PIPERACILLIN AND TAZOBACTAMGeneric (ANDA)
ANDA 208675 · SAGENT PHARMS INC
- 2019PIPERACILLIN AND TAZOBACTAMGeneric (ANDA)
ANDA 212287 · ASTRAL
- 2018PIPERACILLIN AND TAZOBACTAMGeneric (ANDA)
ANDA 204959 · SHANDONG
- 2018PIPERACILLIN AND TAZOBACTAMGeneric (ANDA)
ANDA 203719 · FRESENIUS KABI
- 2018PIPERACILLIN AND TAZOBACTAMGeneric (ANDA)
ANDA 203720 · FRESENIUS KABI
- 2018PIPERACILLIN AND TAZOBACTAMGeneric (ANDA)
ANDA 206204 · FRESENIUS KABI USA
- 2017PIPERACILLIN AND TAZOBACTAMGeneric (ANDA)
ANDA 206996 · APOTEX
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
